We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Wine-Related Cancer Treatment Shows Promise Against Neuroblastomas

By LabMedica International staff writers
Posted on 12 Mar 2009
Resveratrol--the intriguing substance that seems to make red wine heart-healthy--is being proposed for clinical trials later in 2009 as a treatment against neuroblastoma, a type of cancer that affects infants and young children. More...


Dr. Arthur Polans, professor of ophthalmology and visual sciences at the University of Wisconsin School of Medicine and Public Health (UW; Madison, USA) and the UW Paul P. Carbone Comprehensive Cancer Center, has been studying the substance for about five years, and has been using it successfully to treat several types of cancer in mice. His research group has applied for permission to use it to treat neuroblastoma, a nervous-system cancer that mostly affects infants and children.

"Resveratrol is a promising treatment for young children because it's not toxic to healthy cells, only to cancer cells,'' Dr. Polans said. "How do you treat infants without causing other problems in the years to come? That is the kind of question that intrigues us.”

Because it seems to kill cancer kills while leaving healthy tissue alone, resveratrol is also being looked at to treat ocular or uveal melanoma, a cancer of the eye that can lie dormant for many years before metastasizing and becoming fatal. So far, there are no good treatments for melanoma that begins in the colored tissues of the eye; it doesn't respond the same way as melanoma that begins in the skin. "It's one of those rotten cancers,'' Dr. Polans noted. "We don't know what causes it and we don't know how to treat it effectively.”

While the cancers are very different, adults who develop melanoma of the eye have something in common with babies who develop neuroblastoma--they may live for a long time after their diagnosis, so potential treatments shouldn't cause other health problems.

"What neuroblastoma and uveal melanoma have in common is the factor of time,” said Dr. Polans. "Ideally, you'd like to be able to treat them aggressively at first, and then treat them with lower doses of a non-toxic compound over time. Otherwise, you run the risk of damage to vital organs or an increase in secondary tumors.”

So far, the Polans lab has shown that resveratrol shrinks tumors and kills malignant cells in five types of cancer: skin melanoma, breast cancer, neuroblastoma, ocular melanoma and retinoblastoma. A poster outside Dr. Polans' office shows a mouse with a large neuroblastoma tumor that is then shrunken to nothing by resveratrol. "Mice that were treated with resveratrol are healthy, gain weight, and don't seem to have side effects,'' he said, "but when you look at the cancer cells, they're dying.”

Dr. Polans' lab has also done a lot of essential research on resveratrol, developing new forms of the compound that are more potent, and active in the body for longer than the common forms of the substance.

If it shows to be effective, resveratrol will join a large class of cancer-fighting compounds derived from plants, including taxol, which comes from yew trees, and etopside, derived from the mayapple. Resveratrol, which can be derived from grape skins, is also seen as the substance at work in the so-called "French Paradox,'' in which French hearts stay healthy (due to drinking red wine) in spite of all the high fat foods consumed.

"About 70% of new chemotherapeutics are derived from natural products or based on their structures,'' concluded Dr. Polans. "There's a lot of interest worldwide in finding new substances from plants and other natural sources, including microbes from the soil and a variety of species from the ocean.”

Related Links:

University of Wisconsin School of Medicine and Public Health



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automatic CLIA Analyzer
Shine i6000
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Guardant Health has introduced new applications for Guardant360 Liquid, expanding the test’s capabilities for treatment selection in breast and lung cancers. (Photo courtesy of Guardant Health)

Liquid Biopsy Expands Insights Into Treatment Response and Tumor Alterations

Treatment selection in advanced breast and lung cancers can be challenging when traditional biomarkers are absent and genomic findings alone do not fully clarify which therapies may be effective.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: VITEK PRO combines microbial identification and antimicrobial susceptibility testing on a single platform to support routine microbiology workflows and antibiotic selection. (Photo courtesy of bioMérieux)

Automated Microbial Identification and Susceptibility System Gains FDA Clearance

Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: The collaboration aims to expand access to the technology through a regulated clinical diagnostics pathway in Japan.

Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan

Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.